17 results about "Increasing insulin" patented technology

Disclosed herein are apparatuses and methods that can provide a delayed bolus calculator for use in closed loop diabetes therapy that can account for additional factors not taken into account in regular meal bolus calculations when a user wants to deliver a meal bolus a period of time after a meal was consumed. A delayed bolus calculator can enable the user to enter a period of time since the meal was consumed in addition to the number of carbohydrates consumed in a meal. This enables the system to account for the amount of increased insulin from the closed loop algorithm in response to the meal and / or the time since the meal to ensure that the risk of hypoglycemia is mitigated while still reducing hyperglycemia.

The invention discloses an alarm device of an insulin pump in a magnetic resonance examination scene, and relates to the technical field of medical instruments, the alarm device comprises a pumping mechanism, the pumping mechanism comprises a shell, the inner wall of the shell is fixedly connected with a medicine feeding cylinder and a battery, and the shell is internally provided with an alarm mechanism; the alarm mechanism comprises a magnetic field alarm unit, the magnetic field alarm unit is arranged in the shell, the magnetic field alarm unit is used for detecting a magnetic field in a magnetic resonance examination scene and giving an alarm, the alarm mechanism further comprises an alarm auxiliary unit, and the alarm auxiliary unit is arranged in the magnetic field alarm unit. The alarm device for the insulin pump in the magnetic resonance examination scene can give an alarm in time after a patient wears the insulin pump to enter the magnetic resonance examination scene, so that data disorder or loss caused by damage of electronic components in the insulin pump due to the fact that the patient wears the insulin pump to carry out magnetic resonance examination is avoided; and the use safety and reliability of the insulin pump are effectively improved.

Provided is a use of a G protein-coupled receptor kinase 2 (GRK2) degradation compound in lowering blood glucose, stimulating or increasing insulin secretion, or preventing or treating a disease or disorder related thereto. Specifically, provided is a use of a compound represented by Formula (1) that degrades G protein-coupled receptor kinase 2 (GRK2) or a pharmaceutically acceptable salt, an isomer, an isotope, a prodrug, a solvate, or a polymorph thereof or a pharmaceutical composition comprising the same in lowering blood glucose, stimulating or increasing insulin secretion, or preventing or treating a disease or disorder that is ameliorable by lowering blood glucose, for example a pre-diabetic condition, a diabetes, or a complication related to a pre-diabetic condition or a diabetes in a subject in need thereof.

The invention is applicable to the technical field of biological medicines, provides application of ophiopogon japonicus borneol glycoside in preparation of a medicine for preventing and treating gestational metabolic diseases, and aims to solve the technical problems that the conventional medicine is limited in use during pregnancy, and the curative effect and the safety are difficult to take into account. According to verification of multi-model systems such as animals, cells and human-derived trophoblast organs, it is found that ophiopogon japonicus borneol glycoside can significantly improve gestational glycometabolism disorder, improve insulin sensitivity and reduce insulin resistance, and therefore effective intervention on gestational diabetes mellitus is achieved. As a natural component derived from the Zhejiang radix ophiopogonis, the radix ophiopogonis borneol glycoside has definite pharmacological activity and excellent safety, and the Zhejiang radix ophiopogonis is listed in a national homology of medicine and food, so that reliable safety guarantee is provided for use during pregnancy.

The present disclosure is generally directed to the use of biomaterial scaffolds engineered with SA-FasL for the transplantation of stem cell derived β-cells as a treatment for Type I diabetes. Early engraftment post-transplantation and subsequent maturation of these β-cells may be limited by the initial inflammatory response, which impacts the ability to sustain normoglycemia at long times. The survival and development of immature hPSC-derived β-cells transplanted on poly(lactide-co-glycolide) (PLG) microporous scaffolds into the peritoneal fat, a site being considered for clinical translation, was investigated. The scaffolds were modified with biotin for binding of a streptavidin-FasL (SAFasL) chimeric protein to modulate the local inflammatory microenvironment. The presence of FasL impacted infiltration of monocytes and neutrophils and altered their phenotypic response. Conditioned media generated from scaffolds explanted at day 4 did not impact hPSC-derived β-cell survival and maturation in vitro, which was not observed with unmodified scaffolds. Following transplantation, β-cell viability and differentiation were improved with SA-FasL modification. A sustained increase in insulin positive cell ratio was observed with SA-FasL modified relative to unmodified scaffolds. These results demonstrate that SA-FasL-modified scaffolds can mitigate initial inflammatory response and enhance β-cell engraftment and differentiation.

The present invention belongs to the technical fields of protein and genetic engineering. Specifically, it discloses the use of erythropoietin-producing hepatocyte receptor B4 as a target in screening and preparing biological agents or drugs for increasing insulin sensitivity. It also discloses the use of erythropoietin-producing hepatocyte receptor B4 in generating an insulin-sensitized mouse model. Based on the regulation of insulin signaling, a protein, EphB4, capable of interacting with the insulin receptor (InsR), was discovered. This protein can interact with InsR, and insulin stimulation can promote the interaction between the two, which provides a basis for insulin resistance in cases of hyperinsulinemia. Overexpression of EphB4 can promote the degradation of InsR, while suppression of EphB4 can increase insulin sensitivity and improve insulin resistance.

The present invention relates to a novel (Lactobacillus fermentum) strain. In addition, the present invention relates to a composition comprising the strain. In addition, the present invention relates to use of the Lactobacillus fermentum strain or the composition comprising the strain, in the treatment, alleviation, or prevention of metabolic diseases of a subject. The Lactobacillus fermentum strain of the present invention may inhibit the production of nitric oxide (NO) in a subject, increase the secretion of glucagon-like peptide-1 (GLP -1), which is a hormone that regulates blood glucose, by increasing insulin secretion and inhibiting glucagon secretion, reduce blood glucose, and suppress appetite or reduce body weight. Therefore, the strain and the composition comprising same of the present invention may be used for anti-inflammatory purposes, and may also be used for the treatment, alleviation, or prevention of metabolic diseases.

The invention relates to a fusion protein, a recombinant vector, a host cell and application thereof. According to the fusion protein, a complementary fluorescent molecule is inserted into a proinsulin precursor, the complementary fluorescent molecule is composed of a first fragment and a second fragment, the first fragment is located between a B peptide chain and a C peptide chain of the proinsulin precursor, and the second fragment is connected to the C tail end of an A peptide chain of the proinsulin precursor. The fusion protein can be folded into insulin with fluorescence after being sheared by the signal peptide and the C peptide chain, and can be used for indicating the content of insulin in cells. The recombinant expression vector or the host cell can be used for constructing a cell model. The cell model is used for screening compounds capable of promoting proinsulin maturation and increasing insulin content, and a lead compound is screened by using a high-throughput compound library screening method so as to evaluate the potential therapeutic effect or side effect of the lead compound and serve as a candidate molecule for subsequent drug development and commercialization.

The invention discloses a hydrogel modified glimepiride nano-drug as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) dissolving an ERLPO polymer and glimepiride into acetone at 40 DEG C to form a uniform organic solvent; (2) stirring the GLM-ERLPO and BP, and centrifuging after the stirring is finished; (3) adding an ENTPD3 antibody, and stirring for reaction; and (4) carrying out hydrogel wrapping to generate a final product GLM-ERLPO-BP-ENTPD3 (at) GEL. The nano-drug provided by the invention can be applied to treating type 2 diabetes and improving the oral nano-drug applied to glimepiride, is high in drug loading rate and good in biocompatibility, can effectively reduce the blood sugar of a mouse with the type 2 diabetes and increase the secretion of insulin from the source, improves the bioavailability of the glimepiride in a body, and can be used for preparing the glimepiride oral nano-drug for treating the type 2 diabetes and the glimepiride oral nano-drug for improving the application of the glimepiride. A new research idea is provided for the application of the glimepiride.

The present disclosure relates to a device for applying electrical stimulation to biological tissues. Specifically, the present disclosure is related to a device for applying anodal / cathodal biphasic electrical stimulation to beta cells of the pancreas. Through application of biphasic stimulation to beta cells of the pancreas, insulin secretion can be increased in an effort to overcome deficiencies associated with diabetic patients.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for improving diabetes mellitus complicated with ejection fraction retention type heart failure, a pharmaceutical preparation, a preparation method and application. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-15 parts of ginseng, 10-30 parts of astragalus membranaceus, 5-15 parts of coptis chinensis, 5-15 parts of polygonum cuspidatum, 10-30 parts of radix puerariae and 20-40 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating mice, FBG and body weight of the mice are not obviously changed, but the insulin sensitivity can be increased, the high glucose state of cardiac metabolism can be improved, the diastolic dysfunction of DM-HFpEF mice can be relieved, meanwhile, the traditional Chinese medicine composition can relieve cardiac microvascular fibrosis by influencing the EndMT process, and the curative effect is good. The invention further illustrates that the traditional Chinese medicine composition mediates cell autophagy to intervene in'cell failure-EndMT 'to improve the potential action mechanism of cardiac fibrosis.

This invention provides a ginger active ingredient composition and its application. The ginger active ingredient composition includes acetylated 12-gingerol, 8-gingereneol, and 10-gingereneol in a mass ratio of (1-3):2:(2-3). The ginger active ingredient composition of this invention can improve glucose tolerance, increase insulin sensitivity, reduce serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, increase high-density lipoprotein levels, reduce the activity of hepatic alanine aminotransferase and aspartate aminotransferase, improve the degree of hepatic fat vacuolar lesions, and reduce the content of lipid metabolism-related metabolites in obese individuals. Simultaneously, acetylation of 12-gingerol improves its lipid solubility, enhances cell membrane penetration, reduces oxidative degradation of phenolic hydroxyl groups, and improves stability. Furthermore, it releases free 12-gingerol after enzymatic hydrolysis, achieving a sustained-release effect.

The present invention relates to a composition for increasing insulin sensitivity or ameliorating insulin resistance, comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient, and a use thereof. More specifically, the present invention relates to a composition for increasing insulin sensitivity or ameliorating insulin resistance, comprising 1,1-diethoxyethane as an active ingredient as a PTEN oxidative inhibitor, and a use thereof, for example, a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition as a composition for preventing, treating, or ameliorating diseases related to insulin resistance.

The present invention relates to a peptide having anti-obesity and anti-diabetes activities and uses thereof. The peptide of the present invention increases the expression of insulin genes and genes of PDX1 and GLP1R involved in insulin secretion, increases the secretion of insulin itself, and increases the expression levels of phospho-CREB and POMC factors associated with satiety signaling. In addition, the peptide of the present invention exhibits anti-obesity activity. Therefore, the peptide of the present invention can be used for treating, preventing, and alleviating obesity or diabetes, and can be advantageously used for lowering blood glucose levels of a person in need of blood glucose control.

The invention provides application of PCTR1 in preparation of drugs for preventing or treating metabolic dysfunction related diseases. Experimental results show that the PCTR1 can relieve HFD-induced obesity, obviously reduce fat accumulation quality, improve lipid metabolism disorder, reduce serum triglyceride and total cholesterol levels, increase insulin sensitivity, improve the blood sugar regulation capacity of an organism and reduce the fatty liver degree, and has the potential of being developed into drugs for treating metabolic dysfunction related diseases.

Disclosed are compositions and methods for treating or preventing symptoms of a metabolic disorder, replenishing pancreatic β cells, increasing insulin production, and regulating glucose homeostasis. The disclosed methods include administering a pharmaceutical formulation containing an effective amount of Stanniocalcin-2 (STC2) protein, its fragment, or nucleic acid encoding STC2 proteins to a subject in need thereof. This treatment can ameliorate metabolic diseases such as Diabetes Mellitus (Type 1 and Type 2), and hyperglycemia. Also disclosed are pharmaceutical formulations containing STC2 proteins / fragments or nucleic acids. The among of STC2 proteins / fragments or nucleic acids in the pharmaceutical formulations is effective to increase β-cell number, α cell number, the α cell / β cell ratio, pancreatic islet size, pancreatic islet number, the expression of proliferation-associated transcription factors, and / or prevent loss or damage of pancreatic β-cells via degeneration or apoptosis or a combination thereof.